IP Verse

Compositions Of 1-(4-Bromo-5-(1-Ethyl-7-(Methylamino)-2-Oxo-1,2-Dihydro-1,6-Naphthyridin-3-Yl)-2-Fluorophenyl)-3-Phenylurea - EP4084779

The patent EP4084779 was granted to Deciphera Pharmaceuticals on Oct 9, 2024. The application was originally filed on Dec 30, 2020 under application number EP20848921A. The patent is currently recorded with a legal status of "Granted And Under Opposition".

EP4084779

DECIPHERA PHARMACEUTICALS
Application Number
EP20848921A
Filing Date
Dec 30, 2020
Status
Granted And Under Opposition
Sep 6, 2024
Grant Date
Oct 9, 2024
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

ALFRED E TIEFENBACHERMay 28, 2025HAMM & WITTKOPPADMISSIBLE

Patent Citations (7) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONUS7780988
DESCRIPTIONUS8343550
EXAMINATIONWO2020185812
INTERNATIONAL-SEARCH-REPORTUS8461179
INTERNATIONAL-SEARCH-REPORTWO2020185812
OPPOSITIONEP2858646
OPPOSITIONWO2016111725

Non-Patent Literature (NPL) Citations (10) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
OPPOSITION- Dave A. Miller; Marco Gil , " Chapter 10 Spray-Drying Technology", Dave A. Miller; Marco Gil , Williams III, R.O., Formulating Poorly Water-Soluble Drugs, Springer, (20111203), pages 363 - 442, doi:10.1007/978-1-4614-1144-4_10, XP009556892
OPPOSITION- Justin R. Hughey and Robert O. Williams III, "3 Solid-State Techniques for Improving Solubility", Justin R. Hughey and Robert O. Williams III, D5a - Williams III, R.O., Formulating Poorly Water-Soluble Drugs, Springer, (2012), pages 95 - 131, doi:10.1007/978-1-4614-1144-4, ISBN 978-1-4614-1143-7, XP009556890
OPPOSITION- Navnit Shah, Harpreet Sandhu, Duk Soon Choi, Oskar Kalb, Susanne Page, and Nicole Wyttenbach, "8 Structured Development Approach for Amorphous Systems..", Navnit Shah, Harpreet Sandhu, Duk Soon Choi, Oskar Kalb, Susanne Page, and Nicole Wyttenbach, D5b - Williams III , R.O., Formulating Poorly Water-Soluble Drugs, Springer, (2012), pages 267 - 310, doi:10.1007/978-1-4614-1144-4, ISBN 978-1-4614-1143-7, XP009556891
OPPOSITION- B. D. Smith, "Ripretinib (DCC-2618) Is a Switch Control Kinase Inhibitor of a Broad Spectrum of Oncogenic and Drug-Resistant KIT and PDGFRA Variants", Cancer Cell, (20190513), vol. 35, doi:10.1016/j.ccell.2019.04.006, XP055738739
OPPOSITION- Konno, H. ; Handa, T. ; Alonzo, D.E. ; Taylor, L.S., "Effect of polymer type on the dissolution profile of amorphous solid dispersions containing felodipine", European journal of pharmaceutics and biopharmaceutics, ELSEVIER SCIENCE PUBLISHERS B.V., AMSTERDAM., NL, NL , (20081001), vol. 70, no. 2, doi:10.1016/j.ejpb.2008.05.023, ISSN 0939-6411, pages 493 - 499, XP025470891
OPPOSITION- J.M. Miller, "A Win-Win Solution in Oral Delivery of Lipophilic Drugs: Supersaturation via Amorphous Solid Dispersions Increases Apparent Solubility without Sacrifice of Intestinal Membrane Permeability", Mol. Pharmaceutics, (2012), vol. 9, doi:10.1021/mp300104s, XP055812634
OPPOSITION- Dwayne T. Friesen, Ravi Shanker, Marshall Crew, Daniel T. Smithey, W. J. Curatolo, J. A. S. Nightingale, "Hydroxypropyl Methylcellulose Acetate Succinate-Based Spray-Dried Dispersions: An Overview", Molecular Pharmaceutics, American Chemical Society, (20081201), vol. 5, no. 6, doi:10.1021/mp8000793, ISSN 15438384, pages 1003 - 1019, XP055056966
OPPOSITION- Tanno Fumié; Nishiyama Yuichi; Kokubo Hiroyasu; Obara Sakaé, "Evaluation of hypromellose acetate succinate (HPMCAS) as a carrier in solid dispersions.", Journal Drug Development and Industrial Pharmacy, NEW YORK, NY, US, US , (20040101), vol. 30, no. 1, doi:10.1081/DDC-120027506, ISSN 0363-9045, pages 9 - 17, XP009124621
OPPOSITION- Nemunaitis John, Bauer Sebastian, Blay Jean-Yves, Choucair Khalil, Gelderblom Hans, George Suzanne, Schöffski Patrick, Mehren Margaret Von, Zalcberg John, Achour Haroun, Ruiz-Soto Rodrigo, Heinrich Michael C, "Intrigue: Phase III Study of Ripretinib Versus Sunitinib in Advanced Gastrointestinal Stromal Tumor After Imatinib", FUTURE ONCOLOGY, FUTURE MEDICINE LTD., LONDON, GB, GB , (20200131), vol. 16, no. 1, doi:10.2217/fon-2019-0633, ISSN 1479-6694, pages 4251 - 4264, XP093202201
OPPOSITION- Dallas B. Warren, "Using polymeric precipitation inhibitors to improve the absorption of poorly water-soluble drugs: A mechanistic basis for utility", Journal of Drug Targeting, (20101201), vol. 18, no. 10, doi:10.3109/1061186X.2010.525652, ISSN 1061-186x, pages 704 - 731, XP008152135

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents